CYTHWCyclo Therapeutics, Inc.
—Mkt Cap: —P/E: —553d ago
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol C…
Industry Peers
Drug Manufacturers - General$1.06TUSDP/E 39.7
$655.37BUSDP/E 31.5
$470.55BUSDP/E 75.0
$366.84BUSDP/E 119.0
$334.82BUSDP/E 24.0
$279.18BUSDP/E 22.2
$263.35BUSDP/E 22.2
$260.71BUSDP/E 25.2
$257.68BUSDP/E 24.9
$244.85BUSDP/E 25.1
$226.05BUSDP/E 26.0
$210.58BUSDP/E 24.9
$188.73BUSD
$170.97BUSDP/E 9.7
$163.69BUSDP/E 37.8
$130.49BUSDP/E 14.1
$99.54BUSDP/E 16.0
$98.67BUSDP/E 22.4
$93.76BUSDP/E 22.3
$80.98BUSDP/E 15.8
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)870.73K $
Gross Profit794.48K $
Net Income (TTM)-24.80M $
Revenue/Share0.0320 USD
Last Price—
Fiscal Year End—
MR Quarter—
Employees8
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.07
EPS (TTM)—
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin91.24%
Oper. Margin-3545.95%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA-284.27%
Growth
Revenue Growth-52.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.52M $
CapEx (TTM)—
FCF Margin-1498.65%
FCF Yield—
Net Debt11.28M $
Net Debt/EBITDA-0.46
Balance Sheet
Debt/Equity—
Current Ratio0.17
Quick Ratio0.06
Book Value/Sh-0.4680 USD
Cash/Share0.0320 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float11.51M
Insiders—
Institutions—
Technical
SMA 500.2266 USD
SMA 2000.1797 USD
Beta-0.57
S&P 52W Chg16.25%
Avg Vol (30d)—
Avg Vol (10d)5.74K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—